| Schedule of Segment Reporting Information, by Segment |
Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the three and six-month periods ended June 30, 2025 and 2024, were as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | Three Months Ended | | Three Months Ended | | | June 30, 2025 | | June 30, 2024 | | | Cardiovascular | | Endoscopy | | Consolidated | | Cardiovascular | | Endoscopy | | Consolidated | Net sales | | $ | 364,025 | | $ | 18,437 | | $ | 382,462 | | $ | 327,815 | | $ | 10,188 | | $ | 338,003 | Cost of sales standard(1) | | | 147,710 | | | 4,342 | | | | | | 140,492 | | | 3,256 | | | | Cost of sales other(2) | | | 43,949 | | | 1,974 | | | | | | 32,828 | | | 327 | | | | Selling, general and administrative expenses | | | 107,673 | | | 5,424 | | | | | | 91,634 | | | 2,951 | | | | Research and development expenses | | | 23,306 | | | 1,061 | | | | | | 19,643 | | | 620 | | | | Other operating expenses(3) | | | 143 | | | — | | | | | | 306 | | | — | | | | | | | | | | | | | | | | | | | | | | | Income from operations | | $ | 41,244 | | $ | 5,636 | | $ | 46,880 | | $ | 42,912 | | $ | 3,034 | | $ | 45,946 | | | | | | | | | | | | | | | | | | | | Total other expense — net | | | | | | | | | (3,501) | | | | | | | | | (103) | | | | | | | | | | | | | | | | | | | | Income before income taxes | | | | | | | | $ | 43,379 | | | | | | | | $ | 45,843 |
| | | | | | | | | | | | | | | | | | | | | Six Months Ended | | Six Months Ended | | | June 30, 2025 | | June 30, 2024 | | | Cardiovascular | | Endoscopy | | Consolidated | | Cardiovascular | | Endoscopy | | Consolidated | Net sales | | $ | 702,738 | | $ | 35,075 | | $ | 737,813 | | $ | 641,189 | | $ | 20,322 | | $ | 661,511 | Cost of sales standard(1) | | | 286,151 | | | 8,705 | | | | | | 273,558 | | | 6,365 | | | | Cost of sales other(2) | | | 81,732 | | | 4,718 | | | | | | 68,130 | | | 643 | | | | Selling, general and administrative expenses | | | 208,647 | | | 11,936 | | | | | | 182,934 | | | 6,079 | | | | Research and development expenses | | | 45,260 | | | 1,585 | | | | | | 40,559 | | | 1,186 | | | | Other operating expenses(3) | | | 1,166 | | | — | | | | | | 189 | | | — | | | | | | | | | | | | | | | | | | | | | | | Income from operations | | $ | 79,782 | | $ | 8,131 | | $ | 87,913 | | $ | 75,819 | | $ | 6,049 | | $ | 81,868 | | | | | | | | | | | | | | | | | | | | Total other expense — net | | | | | | | | | (6,576) | | | | | | | | | (1,677) | | | | | | | | | | | | | | | | | | | | Income before income taxes | | | | | | | | $ | 81,337 | | | | | | | | $ | 80,191 |
| (1) | Cost of sales standard represents costs of goods sold measured at the internal standard cost for production of inventory. Inventory standard costs include material, labor and manufacturing overhead. |
| (2) | Cost of sales other for all segments includes amortization expense associated with our developed technology and license agreement intangible assets, freight and handling associated with shipments to customers, provisions based on estimated excess, slow moving and obsolete inventories, manufacturing and price variances, and royalties. |
| (3) | Other operating expenses include contingent consideration expense (benefit) related to the changes in fair value of contingent payments associated with acquisitions. |
Total depreciation and amortization by operating segment for the three and six-month periods ended June 30, 2025 and 2024, consisted of the following (in thousands): | | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | June 30, | | June 30, | | | 2025 | | 2024 | | 2025 | | 2024 | Cardiovascular | | $ | 28,767 | | $ | 23,964 | | $ | 55,737 | | $ | 47,352 | Endoscopy | | | 2,254 | | | 127 | | | 4,576 | | | 338 | Total | | $ | 31,021 | | $ | 24,091 | | $ | 60,313 | | $ | 47,690 |
|